- Home
- PSNL vs CGBD Comparison
PSNL vs CGBD Comparison
Compare PSNL & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- CGBD
- Stock Information
- Founded
- PSNL 2011
- CGBD 2012
- Country
- PSNL United States
- CGBD United States
- Employees
- PSNL N/A
- CGBD N/A
- Industry
- PSNL Medical Specialities
- CGBD Finance: Consumer Services
- Sector
- PSNL Health Care
- CGBD Finance
- Exchange
- PSNL Nasdaq
- CGBD Nasdaq
- Market Cap
- PSNL 854.8M
- CGBD 881.4M
- IPO Year
- PSNL 2019
- CGBD 2017
- Fundamental
- Price
- PSNL $8.86
- CGBD $12.60
- Analyst Decision
- PSNL Strong Buy
- CGBD Hold
- Analyst Count
- PSNL 5
- CGBD 5
- Target Price
- PSNL $8.70
- CGBD $14.25
- AVG Volume (30 Days)
- PSNL 1.3M
- CGBD 557.6K
- Earning Date
- PSNL 11-04-2025
- CGBD 11-04-2025
- Dividend Yield
- PSNL N/A
- CGBD 12.83%
- EPS Growth
- PSNL N/A
- CGBD N/A
- EPS
- PSNL N/A
- CGBD 1.14
- Revenue
- PSNL $80,317,000.00
- CGBD $234,464,000.00
- Revenue This Year
- PSNL N/A
- CGBD $15.09
- Revenue Next Year
- PSNL $29.83
- CGBD $5.69
- P/E Ratio
- PSNL N/A
- CGBD $10.90
- Revenue Growth
- PSNL 0.36
- CGBD N/A
- 52 Week Low
- PSNL $2.83
- CGBD $11.65
- 52 Week High
- PSNL $10.95
- CGBD $18.64
- Technical
- Relative Strength Index (RSI)
- PSNL 52.03
- CGBD 45.65
- Support Level
- PSNL $9.40
- CGBD $12.40
- Resistance Level
- PSNL $10.06
- CGBD $13.05
- Average True Range (ATR)
- PSNL 0.89
- CGBD 0.25
- MACD
- PSNL -0.18
- CGBD 0.05
- Stochastic Oscillator
- PSNL 10.20
- CGBD 38.59
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.